Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus INVOKAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus INVOKAMET.
ACTOPLUS MET vs INVOKAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
INVOKAMET is a combination of canagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Canagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
Oral: Starting dose: 5 mg canagliflozin/500 mg metformin hydrochloride extended-release twice daily; titrate based on efficacy and tolerability, maximum 150 mg/1000 mg twice daily.
None Documented
None Documented
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Canagliflozin: 10–13 hours (multiple dosing); Metformin: 6.2 hours (plasma). Accumulation occurs in renal impairment.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Canagliflozin (SGLT2 inhibitor): ~33% renal (1% unchanged, ~33% as glucuronide metabolites), ~52% fecal. Metformin (biguanide): 90% renal unchanged via tubular secretion.
Category C
Category C
Thiazolidinedione/Biguanide Combination
SGLT2 Inhibitor / Biguanide Combination